582 related articles for article (PubMed ID: 26579564)
1. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
Sawlani RN; Raizer J; Horowitz SW; Shin W; Grimm SA; Chandler JP; Levy R; Getch C; Carroll TJ
Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772
[TBL] [Abstract][Full Text] [Related]
4. Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma.
Bonekamp D; Mouridsen K; Radbruch A; Kurz FT; Eidel O; Wick A; Schlemmer HP; Wick W; Bendszus M; Østergaard L; Kickingereder P
J Cereb Blood Flow Metab; 2017 Feb; 37(2):485-494. PubMed ID: 26861817
[TBL] [Abstract][Full Text] [Related]
5. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
[TBL] [Abstract][Full Text] [Related]
6. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
7. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
8. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J
Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
[TBL] [Abstract][Full Text] [Related]
9. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
10. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
11. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
[TBL] [Abstract][Full Text] [Related]
13. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
Pichler J; Pachinger C; Pelz M; Kleiser R
Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
[TBL] [Abstract][Full Text] [Related]
14. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
[TBL] [Abstract][Full Text] [Related]
16. Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.
Stadlbauer A; Pichler P; Karl M; Brandner S; Lerch C; Renner B; Heinz G
Eur J Radiol; 2015 Jun; 84(6):1128-36. PubMed ID: 25795194
[TBL] [Abstract][Full Text] [Related]
17. Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.
Andre JB; Nagpal S; Hippe DS; Ravanpay AC; Schmiedeskamp H; Bammer R; Palagallo GJ; Recht L; Zaharchuk G
Neuroradiol J; 2015 Apr; 28(2):112-9. PubMed ID: 25923677
[TBL] [Abstract][Full Text] [Related]
18. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab.
Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Pope WB
Magn Reson Med; 2012 Jan; 67(1):237-45. PubMed ID: 21702063
[TBL] [Abstract][Full Text] [Related]
19. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.
Grossmann P; Narayan V; Chang K; Rahman R; Abrey L; Reardon DA; Schwartz LH; Wen PY; Alexander BM; Huang R; Aerts HJWL
Neuro Oncol; 2017 Nov; 19(12):1688-1697. PubMed ID: 28499022
[TBL] [Abstract][Full Text] [Related]
20. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.
Hattingen E; Jurcoane A; Daneshvar K; Pilatus U; Mittelbronn M; Steinbach JP; Bähr O
Neuro Oncol; 2013 Oct; 15(10):1395-404. PubMed ID: 23925453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
